Almac selected as preferred partner for EORTC clinical trials

By Melissa Fassbender

- Last updated on GMT

Almac selected as preferred partner for EORTC clinical trials

Related tags Cancer

Almac Diagnostics will initiate sample profiling on current EORTC trials to further biomarker discovery and development.

Through the partnership, Almac Diagnostics will support molecular profiling of cancer patient samples collected by the European Organization for the Research and Treatment of Cancer (EORTC) and SPECTA (Screening Patients for Effective Clinical Trial Access).

"The ​SPECTA Program team require a partner to provide consistent, quality analysis of samples from their clinical trials​," Michael Sloan, VP Business Development, Almac Diagnostics, told

"They sought a partner who can provide a robust quality service and support the discovery, development and ultimately commercialization of biomarkers​."

Specifically, Almac Diagnostics will analyze patterns of genomic variation within patient samples using the new Illumina Trusight Tumor 170 solid tumor NGS panel.

"This partnership will provide a consistent approach to biomarker discovery and development from these valuable European clinical trial samples​," added Sloan.

The partnership is set to last for an "indefinite period of time," ​Sloan explained, and no further investment is required on Almac's part as the company has "significant​" capacity available. 

The services will be provided from Almac’s European facility in Craigavon, Northern Ireland.

The SPECTA infrastructure

Vassilis Golfinopoulos, EORTC Medical Director said the agreement with Almac is one of “several key partnership​” established to advance the SPECTA infrastructure.

The organization ultimately hopes to simplify patient inclusion in clinical trials of molecularly targeted treatment.

It is also looking to standardize Next Generation Sequencing (NGS) and Gene Expression Analysis in translational research projects in order to improve reproducibility and comparability of results.

(Feature image: iStock/manaemedia)

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more